|
GR 125,743
|
|
148547-33-5
|
|
PF-3845
|
|
1196109-52-0
|
|
Ro0335
|
|
867365-76-2
|
|
CITCO
|
|
338404-52-7
|
|
ALW-II-49-7
|
|
1135219-23-6
|
|
Todralazine hydrochloride
|
|
3778-76-5
|
|
Benzenepropanoicacid
|
|
26347-98-8
|
|
SG-094
|
|
|
|
UPGL00004
|
|
1890169-95-5
|
|
TH34
|
|
2196203-96-8
|
|
RG 14620
|
|
136831-49-7
|
|
Buspirone Impurity
|
丁螺環(huán)酮雜質(zhì)
|
2726492-72-2
|
|
|
非奈利酮雜質(zhì)
|
41935-71-1
|
|
|
2-(2,6-二氯-3,5-二甲氧基苯基)乙腈
|
869882-16-6
|
|
Gsk484 hydrochloride
|
|
1652591-81-5
|
|
THAL-SNS-032
|
|
2139287-33-3
|
|
VH032
|
|
1448188-62-2
|
|
DBRD9
|
|
2170679-45-3
|
|
ASTX660
|
|
1799328-86-1
|
|
BMS-P5
|
|
1550371-22-6
|
|
CA-4948
|
|
1801343-74-7
|
|
Laninamivir
|
拉尼米韋
|
203120-17-6
|
|
BI-2865
|
(4S)-2-氨基-4,5,6,7-四氫-4-甲基-4-[3-[4-[(1S)-1-[(2S)-1-甲基-2-吡咯烷基]乙氧基]-2-嘧啶基]-1,2,4-惡二唑-5-基]苯并[b]噻吩-3-甲腈
|
2937327-93-8
|
|
JNJ-18038683
|
|
851376-05-1
|
|
Aumitin
|
|
946293-78-3
|
|
RAD51-IN-17
|
|
2101739-18-6
|
|
CK1-IN-1
|
|
1784751-20-7
|
|
SERALUTINIB
|
|
1619931-27-9
|
|
Finasteride Carboxaldehyde
|
|
154387-61-8
|
|
MLN120B
|
|
783348-36-7
|
|
AMG487
|
|
473719-41-4
|
|
HCV-IN-31
|
|
1998705-62-6
|
|
LRE1
|
|
1252362-53-0
|
|
PDGFR Tyrosine Kinase Inhibitor III
|
|
205254-94-0
|
|
RS 100329
|
|
232953-52-5
|
|
MPT0B014
|
|
1215208-59-5
|
|
(Rac)-Brassinazole
|
|
224047-41-0
|
|
ARV-766
|
4-(4-((1-(4-((反式-3-(4-氰基-3-甲氧基苯氧基)-2,2,4,4-四甲基環(huán)丁基)氨基甲Chemicalbook酰基)苯基)哌啶-4-基)甲基)哌嗪-1-基)-N-((S)-2,6-二氧代嘧啶-3-基)-2-氟苯甲酰胺
|
2750830-09-0
|
|
|
萊特莫韋雜質(zhì)
|
917389-37-8
|
|
MMRi62
|
|
352693-80-2
|
|
C3a receptor agonist 1
|
|
944997-60-8
|
|
BM635
|
|
1493762-74-5
|
|
R-10015
|
2-(1-(5-氯-7H-吡咯并[2,3-D]嘧啶-4-基)哌啶-4-基)-1H-苯并[D]咪唑-6-羧酸甲酯
|
2097938-51-5
|
|
ROCK-IN-5
|
|
692870-25-0
|
|
SAR407899
|
6-(4-哌啶基氧基)-1(2H)-異喹啉酮
|
923359-38-0
|
|
DC-TEADin02
|
|
2380228-45-3
|
|
GRP-60367
|
|
1309241-34-6
|
|
CB-7921220
|
6-(4-氨基苯乙烯基)吡啶-2-羧酸
|
115453-99-1
|
|
KY1220
|
5-((1-(4-硝基苯基)-1H-吡咯-2-基)亞甲基)-2-硫代咪唑烷-4-酮
|
292168-79-7
|
|
RBM013209
|
|
2597933-17-8
|
|
C-DIM 12
|
|
178946-89-9
|
|
AU1235
|
|
1338780-86-1
|
|
C-215
|
|
912780-51-9
|
|
NS 398
|
N-[2-(環(huán)己氧基)-4-硝基苯基]甲基磺酰胺
|
123653-11-2
|
|
(S)-Remoxipride Hydrochloride
|
瑞莫必利鹽酸鹽
|
73220-03-8
|
|
BOS318
|
|
2387633-15-8
|
|
A 438079 hydrochloride
|
3-[[5-(2,3-二氯苯基)-1H-四唑-1-基]甲基]吡啶單鹽酸鹽
|
899431-18-6
|
|
GDC-6036
|
|
2417987-45-0
|
|
EB-3D
|
1,1'-(((乙烷-1,2-二基雙(氧基))雙(4,1-亞苯基))雙(亞甲基))雙(4-(二甲氨基)吡啶-1-鎓)溴化物
|
1839150-63-8
|
|
Letermovir Impurity
|
|
917389-29-8
|
|
|
萊特莫韋雜質(zhì)
|
1791412-04-8
|
|
|
萊特莫韋雜質(zhì)
|
917389-34-5
|
|
GSK215
|
|
2743427-26-9
|
|
Nampt activator-1
|
|
701929-65-9
|
|
BRD4 Inhibitor-20
|
|
2490311-14-1
|
|
CP-447697
|
|
1092847-21-6
|
|
ML148
|
|
451496-96-1
|
|
CCR8 antagonist 1
|
|
723304-76-5
|
|
RS 100329 HCL
|
|
1215654-26-4
|
|
MLN120B.2 HCl
|
|
1782573-78-7
|
|
MS402
|
|
1672684-68-2
|
|
Merafloxacin
|
|
91188-00-0
|
|
TT01001
|
|
1022367-69-6
|
|
LP-471756
|
|
413605-11-5
|
|
hMAO-B-IN-4
|
|
1666119-75-0
|
|
HIF-1 inhibitor-4
|
|
333357-56-5
|
|
p38α inhibitor 3
|
|
260428-69-1
|
|
TH-Z93
|
|
2260887-09-8
|
|
RN-18
|
|
431980-38-0
|
|
VB-124
|
|
2230186-18-0
|
|
TD-106
|
|
2250288-69-6
|
|
BYK 191023 dihydrochloride
|
BYK191023二鹽酸鹽
|
1216722-25-6
|
|
Imiquimod Impurity
|
咪喹莫特雜質(zhì)
|
99010-41-0
|
|
CGP-53716
|
N-(4-甲基-3-((4-(吡啶-3-基)嘧啶-2-基)氨基)苯基)苯甲酰胺
|
152459-94-4
|
|
NAcM-OPT
|
|
2089293-61-6
|
|
TUG-469
|
|
1236109-67-3
|
|
Loreclezole
|
(Z)-1-(2-氯-2-(2,4-二氯苯基)乙烯基)-1H-1,2,4-三唑
|
117857-45-1
|
|
CNX-1351
|
|
1276105-89-5
|
|
|
來特莫韋雜質(zhì)
|
917389-35-6
|
|
Vodobatinib
|
|
1388803-90-4
|
|
Letermovir Impurity
|
1,3-雙(2-甲氧基-5-(三氟甲基)苯基)脲
|
6064-14-8
|
|
SCH529074
|
|
922150-11-6
|
|
ASP7663
|
|
1190217-35-6
|
|
ML402
|
|
298684-44-3
|
|
dTRIM24
|
|
2170695-14-2
|
|
CP-289503
|
|
1349637-14-4
|
|
NLRP3-IN-10
|
|
2641826-39-1
|
|
Olaparib Impurity
|
奧拉帕尼雜質(zhì)
|
2415448-60-9
|
|
FK-3311
|
N-[4-乙?；?2-(2,4-二氟苯氧基)苯基]-甲烷磺酰胺
|
116686-15-8
|
|
BM212
|
1-((1,5-二(4-氯苯基)-2-甲基-1H-吡咯-3-基)甲基)-4-甲基哌嗪
|
146204-42-4
|